Comparing the Effectiveness of Biologic Agents in the Treatment of Rheumatoid Arthritis
An overview of the comparative effectiveness of biologic medications in rheumatoid arthritis.
Disease-Modifying Antirheumatic Drugs
Assessing the Efficacy of DMARDs in Axial Spondyloarthritis Remission
Researchers evaluated the efficacy of biologic disease-modifying antirheumatic drugs in achieving remission in axial spondyloarthritis.
Pain Centralization Associated With Response to DMARD Therapy in Rheumatoid Arthritis
Researchers assessed the association between dysregulated central pain processing and treatment response in rheumatoid arthritis.
Treatment With DMARDs Does Not Alter COVID-19 Susceptibility and Severity
Researchers evaluated the risk for COVID-19 infection and its severity in patients receiving DMARDs.
Similar Rates of COVID-19 Incidence, Severity in Patients With and Without Rheumatic Disease
Researchers compared the incidence and severity of COVID-19 in patients with rheumatic disease receiving DMARDs and the general population.
Treating Newly Diagnosed Juvenile Idiopathic Arthritis With DMARDs: Does Timing Matter?
Researchers evaluated the effectiveness and timing of DMARDs in the treatment of chil-dren with newly diagnosed polyarticular course juvenile idiopathic arthritis.
Factors Examined for Time to First Prescription for Biologic DMARD in RA
For older patients with rheumatoid arthritis (RA), there is considerable variation in time to receipt of first biologic disease-modifying antirheumatic drug (DMARD) after prescription of the first conventional synthetic (cs) DMARD.
Slightly Increased Serious Infection Risk With Biologic vs Synthetic DMARDs in RA
Researchers assessed the most recent safety data of synthetic and biologic disease-modifying antirheumatic drugs to inform the 2019 update of the European League Against Rheumatism recommendations for the management of rheumatoid arthritis.
Methotrexate Monotherapy Is Often Effective for Juvenile Idiopathic Arthritis
This study evaluated the frequency of achieving inactive disease in children with JIA treated solely with methotrexate and identified a model for patients with a lesser likelihood of reaching inactive disease with methotrexate.
Worldwide Access to bDMARDs Influenced by Socioeconomic Status, Prescription Rules
Disease activity in patients with rheumatoid arthritis and access to bDMARD care varies across countries worldwide.
-
Loading...
-
Loading...
Next post in Rheumatoid Arthritis
